Chronic lymphocytic leukemia Market Size, Share and Global Trend By Therapy (Chemotherapy, Targeted Therapy), By Disease Indication (B-cell Chronic Lymphocytic Leukemia, T-cell Chronic Lymphocytic Leukemia), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), and Regional Forecast, 2024-2032

Chronic lymphocytic leukemia (CLL) is slow-growing cancer which begins in lymphocytes in the bone marrow and extends into the blood. It can even spread to lymph nodes and other organs such as spleen and liver. Chronic lymphocytic leukemia is divided into two types, B-cell chronic lymphocytic leukemia and T- cell chronic lymphocytic leukemia. Symptoms of chronic lymphocytic leukemia include enlarged lymph nodes, fever, fatigue, pain in the abdomen due to an enlarged spleen, weight loss, night sweats, frequent infections, and others.

In 2016, the American Cancer Society estimated that in the United States, about 18,960 new cases of chronic lymphocytic leukemia (CLL) and approximately 4,660 deaths by chronic lymphocytic leukemia (CLL) were reported. This rising prevalence and unmet patient needs have attracted many pharmaceutical industries to develop a novel treatment for chronic lymphocytic leukemia.

Rising prevalence of chronic lymphocytic leukemia, rapid adoption of a sedentary lifestyle, and increasing aging population are the major factors driving the global chronic lymphocytic leukemia market. Also, an increased number of research and development in the oncology sector, new drug development, the introduction of novel therapies, and pipeline drug candidates are expected to fuel the global chronic lymphocytic leukemia therapeutics market.

However, the stringent government regulations and inadequate reimbursement policies in emerging countries are factors that can hamper the growth in the global chronic lymphocytic leukemia therapeutics market.

Key Players Covered

Some of the major companies that are present in the global chronic lymphocytic leukemia therapeutics market are Genzyme Corporation, Novartis International AG, Pfizer Inc., Roche Holding AG, Celgene Corporation, Ariad Pharmaceuticals Inc., Clavis Pharma ASA, and Sunesis Pharmaceuticals Inc., and others.

SEGMENTATION 

Among the therapy, targeted therapy segment is anticipated to have a considerable growth over the forecast period, primarily due to the rapid adoption of targeted therapy, increased research, and the gradual shift of pharmaceutical companies towards the development of targeted therapy drugs.

Key Insights

• Prevalence of Chronic lymphocytic leukemia (CLL) for key countries
• The regulatory scenario for key countries
• New product launch
• Patent analysis
• Pipeline snapshot
• Recent industry developments such as partnerships, mergers, and acquisitions

• Regional Analysis:

North America is expected to dominate the global Chronic Lymphocytic Leukemia (CLL) market during the forecast period which can be attributed to the presence of potential pipeline candidates, and increased clinical studies for the development of novel treatment for chronic lymphocytic leukemia. In Europe, the Chronic Lymphocytic Leukemia (CLL) market is projected to expand due to the rising prevalence of Chronic Lymphocytic Leukemia (CLL) and strategic research collaborations. According to Cancer Research UK, it's estimated that around 3,800 new cases of chronic lymphocytic leukemia are diagnosed in the UK every year. Thus, the increasing incidences of chronic lymphocytic leukemia are also expected to boost the demand for chronic lymphocytic leukemia drugs in Europe. The Chronic lymphocytic leukemia (CLL) market in Asia Pacific is projected to have a significant growth in the forecast duration owing to the improving health reimbursement, growing focus towards pharmaemerging countries, and rising awareness about chronic lymphocytic leukemia.

Key Industry Developments

• In May 2019, AbbVie Inc. received the FDA approval for Venclexta in combination with Gazyva for the treatment of chronic lymphocytic leukemia.
• In January 2019, Janssen Global Services, LLC received FDA approval for Imbruvica in combination with obinutuzumab for treatment of patients with chronic lymphocytic leukemia.
• In December 2018, AstraZeneca and Acerta Pharma presented the results of their ongoing clinical studies on Calquence for treating patients with chronic lymphocytic leukemia.